Home > Research > Publications & Outputs > Evaluation of C-reactive protein measurement fo...


Text available via DOI:

View graph of relations

Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members

Research output: Contribution to Journal/MagazineReview articlepeer-review

  • Mario Di Napoli
  • Markus Schwaninger
  • Roberto Cappelli
  • Elena Ceccarelli
  • Giacinto Di Gianfilippo
  • Cristina Donati
  • Hedley C. A. Emsley
  • Sandro Forconi
  • Stephen J. Hopkins
  • Luca Masotti
  • Keith W. Muir
  • Anna Paciucci
  • Francesca Papa
  • Sabina Roncacci
  • Dirk Sander
  • Kerstin Sander
  • Craig J. Smith
  • Alessandro Stefanini
  • Daniela Weber
<mark>Journal publication date</mark>06/2005
Issue number6
Number of pages14
Pages (from-to)1316-1329
Publication StatusPublished
Early online date24/05/05
<mark>Original language</mark>English


Background and Purpose - Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. Summary of Review - CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins. Conclusion - At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.